IPP Bureau
Asahi Songwon Colors acquires remaining 22% stake in Atlas Life Sciences
By IPP Bureau - March 28, 2024
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Caplin Group commences operations of Rs. 150 crore oncology facility
By IPP Bureau - March 28, 2024
The facility will manufacture tablets, capsules, and injections for the oncology segment
EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer
By IPP Bureau - March 28, 2024
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
By IPP Bureau - March 27, 2024
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Data privacy, security and ethical challenges must for adoption of GenAI in healthcare: PwC India
By IPP Bureau - March 27, 2024
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Apollo Cancer Centres heralds a new era in breast cancer surgery
By IPP Bureau - March 27, 2024
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
By IPP Bureau - March 27, 2024
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
By IPP Bureau - March 27, 2024
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Warren Remedies commences commercial production of APIs
By IPP Bureau - March 26, 2024
AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease
By IPP Bureau - March 26, 2024
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
By IPP Bureau - March 23, 2024
Combination shows consistent benefit across prespecified post-progression outcomes
Briefs: Concord Biotech and Neuland Laboratories
By IPP Bureau - March 23, 2024
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Sharon Bio-Medicine resumes operations
By IPP Bureau - March 23, 2024
Operations of Line II was stopped due to a fire incident earlier
'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients
By IPP Bureau - March 23, 2024
Hepatitis B infects over 40 million people in India
